Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jon R. Ward is active.

Publication


Featured researches published by Jon R. Ward.


Journal of Leukocyte Biology | 2005

The low‐toxicity versions of LPS, MPL® adjuvant and RC529, are efficient adjuvants for CD4+ T cells

Bruce S. Thompson; Paula M. Chilton; Jon R. Ward; Jay T. Evans; Thomas C. Mitchell

Lipopolysaccharide (LPS) has long been known to enhance innate and adaptive immune responses; however, its extreme toxicity precludes its use in clinical settings. The combined toxicity and adjuvanticity of LPS have contributed to the view that immunological adjuvants need to be highly inflammatory to be maximally effective. Here, we compared the effects of LPS with its less‐toxic derivatives, monophosphoryl lipid A (MPL) and a chemical mimetic, RC529, on CD4+ T cell clonal expansion, long‐term survival, and T helper cell type 1 (Th1) differentiation. We found that LPS, MPL, and RC529 had similar effects on CD4+ T cell clonal expansion, cell division, and ex vivo survival. Analysis of the ability of activated CD4+ T cells to produce interferon‐γ following a 21‐day immunization and challenge protocol with LPS and MPL resulted in similar Th1 differentiation. In contrast, we found that LPS was more effective in promoting long‐term CD4+ T cell responses, as we recovered nearly sixfold more cells following immunization/challenge as compared with treatment with MPL. Our results indicate that low‐inflammation adjuvants, such as MPL and RC529, are capable of enhancing short‐term CD4+ T cell clonal expansion and Th1 differentiation, but inflammatory signaling aids in the long‐term retention of antigen‐specific T cells.


Vaccine | 2000

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.

Jory R. Baldridge; Yvonne M. Yorgensen; Jon R. Ward; J. Terry Ulrich

The induction of protective immunity stemming from vaccines delivered by mucosal routes is dependent on the development of safe and effective mucosal adjuvants. The immunostimulant monophosphoryl lipid A (MPL(R)) was evaluated for its ability to enhance both systemic and mucosal immunity to three distinct antigens. Vaccines formulated with MPL(R) and hepatitis B surface antigen, tetanus toxoid or influenza antigens were administered by intranasal delivery to mice. In each case the vaccines formulated with MPL(R) resulted in enhanced IgA titers from mucosal samples. Enhanced IgA concentrations were detected in samples from both local and distal mucosal sites. In addition, the MPL(R) formulated vaccines induced systemic immunity characteristic of a Th1-type of response. Serum IgG2a antibody titers were elevated and cytotoxic T cell activity was enhanced.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

David A. Johnson; C. Gregory Sowell; Craig L. Johnson; Mark T. Livesay; David S. Keegan; Michael J. Rhodes; J. Terry Ulrich; Jon R. Ward; John L. Cantrell; Valerie G. Brookshire

A novel series of acylated omega-aminoalkyl 2-amino-2-deoxy-4-phosphono-beta-D-glucopyranosides (aminoalkyl glucosaminide 4-phosphates) was synthesized and screened for immunostimulant activity. Several of these compounds enhance the production of tetanus toxoid-specific antibodies in mice and augment vaccine-induced cytotoxic T cells against EG.7-ova target cells.


Bioorganic & Medicinal Chemistry Letters | 2008

Bace-1 Inhibitors Part 3: Identification of Hydroxy Ethylamines (Heas) with Nanomolar Potency in Cells.

Paul John Beswick; Nicolas Charrier; B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Robert J. Gleave; Julie Hawkins; Ishrut Hussain; Christopher Norbert Johnson; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; John Skidmore; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; A Stuart; Sharon Sweitzer; P Theobald; David Vesey

This article is focusing on further optimization of previously described hydroxy ethylamine (HEA) BACE-1 inhibitors obtained from a focused library with the support of X-ray crystallography. Optimization of the non-prime side of our inhibitors and introduction of a 6-membered sultam substituent binding to Asn-294 as well as a fluorine in the C-2 position led to derivatives with nanomolar potency in cell-based assays.


Journal of Endotoxin Research | 2002

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529

Jory R. Baldridge; Christopher W. Cluff; Jay T. Evans; Michael J. Lacy; Jeffrey Stephens; Valerie G. Brookshire; Rong Wang; Jon R. Ward; Yvonne M. Yorgensen; David H. Persing; David A. Johnson

Earlier we showed that the structural requirements for adjuvanticity among the aminoalkyl glucosaminide 4-phosphate (AGP) class of synthetic immunostimulants may be less strict than those for other endotoxic activities, including the induction of nitric oxide synthase in murine macrophages and cytokine production in human whole blood. The known role of nitric oxide and pro-inflammatory cytokines in the activation of host defenses against infection prompted us to examine the ability of certain AGPs to enhance non-specific resistance in mice to Listeria monocytogenes and influenza infections as well as to stimulate the production of pro-inflammatory cytokines in mouse splenocytes, human PBMCs, and human U937 histiocytic lymphoma cells. Intranasal administration of RC-524 or RC-529 to mice 2 days prior to a lethal influenza challenge provided significant protection in each case. Similarly, the intravenous administration of these AGPs induced resistance to L. monocytogenes infection as measured by survival or reduction of bacteria in the spleen. Activation of the innate immune response by AGPs appears to involve activation of Toll-like receptor 4 (TLR4) because RC-524 failed to elicit a protective effect in C3H/HeJ mice which have a defect in TLR4 signaling or induce significant cytokine levels in C3H/HeJ splenocytes. Both AGPs also stimulated pro-inflammatory cytokine release in human cell cultures in a dose-dependent manner.


Bioorganic & Medicinal Chemistry Letters | 2008

BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).

B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Julie Hawkins; Ishrut Hussain; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; Sharon Sweitzer; P Theobald; David Vesey; Daryl Simon Walter; Jon R. Ward; Gareth Wayne

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimers disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of potent inhibitors based on a hydroxy ethylamine (HEA) transition-state mimetic. These inhibitors were capable of lowering amyloid production in a cell-based assay.


Vaccine | 1997

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity.

Jory R. Baldridge; Jon R. Ward

Vaccines utilizing poorly immunogenic subunit antigens are dependent upon adjuvants to drive the appropriate T cell responses. In an effort to determine the ability of several adjuvants to promote cell-mediated immunity (CMI), we assessed delayed-type hypersensitivity (DTH) in mice inoculated with heat-killed Listeria monocytogenes (HKLM) vaccines. The vaccines were formulated as oil-in-water emulsions containing one or more of the following bacterial-derived immunostimulators: MPL immunostimulant, a monophosphoryl lipid A preparation, synthetic trehalose dicorynomycolate (TDCM) and Mycobacterium phlei cell wall skeleton (CWS). Oil-in-water emulsions containing HKLM without adjuvants did not induce DTH responsiveness in mice. The incorporation of TDCM, or MPL plus TDCM and/or CWS to the formulation enabled the HKLM vaccine to stimulate CMI characterized by DTH responsiveness. Following antigen challenge the resulting increases in footpad thickness ranged from 15-20% and were comparable to the DTH driven by complete Freunds adjuvant. Adjuvants composed of MPL/TDCM and MPL/TDCM/CWS induced responses equivalent to those measured in mice immunized with viable L. monocytogenes, and the responses remained at these levels for at least 2 months. Furthermore, in vivo depletion of CD4+ T cells, but not CD8+ T cells, abrogated the induction and expression of DTH, indicating that the response is mediated by CD4+ T cells.


Bioorganic & Medicinal Chemistry Letters | 2015

Characterization of TRIF Selectivity in the AGP Class of Lipid A Mimetics: Role of Secondary Lipid Chains

Juhienah K. Khalaf; William S. Bowen; Hélène G. Bazin; Kendal T. Ryter; Mark T. Livesay; Jon R. Ward; Jay T. Evans; David A. Johnson

TLR4 agonists that favor TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.


Journal of Medicinal Chemistry | 1999

3-O-Desacyl Monophosphoryl Lipid A Derivatives: Synthesis and Immunostimulant Activities†

David A. Johnson; David S. Keegan; C. Gregory Sowell; Mark T. Livesay; Craig L. Johnson; Lara M. Taubner; Annalivia Harris; Kent R. Myers; Jennifer D. Thompson; Gary L. Gustafson; Michael J. Rhodes; J. Terry Ulrich; Jon R. Ward; Yvonne M. Yorgensen; John L. Cantrell; Valerie G. Brookshire


Bioorganic & Medicinal Chemistry Letters | 2008

Bace-1 Inhibitors Part 2: Identification of Hydroxy Ethylamines (Heas) with Reduced Peptidic Character.

B Clarke; Emmanuel Demont; Colin Dingwall; Rachel Dunsdon; Faller A; Julie Hawkins; Ishrut Hussain; David Timothy Macpherson; Graham Maile; Rosalie Matico; Peter Henry Milner; Julie Mosley; Antoinette Naylor; A O'Brien; Sally Redshaw; Riddell D; Paul Rowland; Soleil; Kathrine J. Smith; Steven James Stanway; Geoffrey Stemp; Sharon Sweitzer; P Theobald; David Vesey; Daryl Simon Walter; Jon R. Ward; Gareth Wayne

Collaboration


Dive into the Jon R. Ward's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David A. Johnson

East Tennessee State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge